HEALTH Research Report Series: Methamphetamine Abuse and Addiction

Chronic abuse can lead to psychotic behavior, characterized by intense paranoia, visual and auditory hallucinations, and out-of-control rages that can be coupled with extremely violent behavior. As with most other chronic diseases, such as diabetes, asthma, or heart disease, treatment for drug addiction generally isn’t a cure. People who are recovering from an addiction will be at risk for relapse for years and possibly for their whole lives. Research shows that combining addiction treatment medicines with behavioral therapy ensures the best chance of success for most patients. Treatment approaches tailored to each patient’s drug use patterns and any co-occurring medical, mental, and social problems can lead to continued recovery.

Meth users in recovery sometimes must have all their teeth pulled and replaced with dentures. When methamphetamine is used for an extended period, users often lose weight, becoming gaunt and haggard. Methamphetamine also creates severe mental changes in users that often include paranoia, aggression, irritability and even psychosis. Increased strain on the heart and accelerated heart rate can predispose the user to stroke.

Meth can sometimes be found in counterfeit pills simulating prescription medications such as oxycodone, hydrocodone, Adderall, and Xanax and other medications. If health professionals admitted the existence of racial disparities, they would have to acknowledge their lack of cultural awareness and make individual changes in their approaches to SUD patients. More importantly, they would have to address issues relevant to structural racism in medicine. Most physicians and others caring for SUD patients do not appear ready to make substantial alterations in their modus operandi within very conservative structures.

Some people may start to feel the need to take more of a drug or take it more often, even in the early stages of their drug use. The National Institute on Drug Abuse (NIDA) is the largest supporter of the world’s research on substance use and addiction. Part of the National Institutes of Health, NIDA conducts and supports biomedical research to advance the science on substance use and addiction and improve individual and public health. Look below for more information on drug use, health, and NIDA’s research efforts.

NIDA also supports research to understand the health impacts of methamphetamine use, including how reducing use affects health and other outcomes. After the acute phase of withdrawal, a person may still experience low mood, anxiety, and cravings for the drug for several months. It was once thought that surges of the neurotransmitter dopamine produced by drugs directly caused the euphoria, but scientists now think dopamine has more to do with getting us to repeat pleasurable activities (reinforcement) than with producing pleasure directly.

• Through grants and contracts awarded to investigators at research institutions around the country and overseas, as well as through its Intramural Research Program, NIDA addresses the most fundamental and essential questions about substance use.
• Brain imaging studies of people with addiction show physical changes in areas of the brain that are critical to judgment, decision-making, learning and memory, and behavior control.12 These changes help explain the compulsive nature of addiction.
• NIDA researchers demonstrate the effectiveness of sublingual buprenorphine for the treatment of opioid use disorder.
• These include problems with self-reporting and the omission of people who are homeless and not living in shelters or are institutionalized.
• 1974 — Congress establishes NIDA as the federal focal point for biomedical research on the nature and extent of substance use and substance use disorders.

Breakthrough pain

Monitoring the Future Study and Population Assessment of Tobacco and Health (PATH) study data show that flavored e-cigarette products particularly appeal to youth. Food and Drug Administration (FDA) policy(link is external) prioritizing enforcement against certain unauthorized flavored cartridge-based products. NIDA-supported research leads to the FDA approval of lofexidine, the first non-opioid treatment for opioid withdrawal. 2010 — NIDA launches its first annual National Drug Facts Week (NDFW), a health observance that inspires dialogue about the science of drug use and addiction among youth. It provides an opportunity for scientists, students, educators, healthcare providers, and community partners to help advance addiction science and address youth drug and alcohol use in communities and nationwide. 1993 — The NIDA Medications Development Program obtains approval from the U.S.

What Happens When Drugs Are Combined?

Death certificates do not always report the specific drugs involved, so death rates could also be underestimated. Because of this risk, experts recommend giving opioid overdose reversal medications such as nalmefene or naloxone (sometimes sold as Narcan) to anyone experiencing slowed or stopped breathing, which may be signs of an opioid overdose. Research also suggests that drug checking approaches, such as fentanyl test strips, can help people understand what is in their drug supply before use.

Looking for Treatment?

Patients in this study who received vouchers for having cocaine negative urine tests were more likely to have sustained cocaine abstinence during outpatient treatment than a comparative group that received incentives regardless of urine test results. NIDA-supported research identifies brain processes that increase the rewarding effects of cocaine the more a person uses it, a change thought to play an important role in the development of cocaine craving and addiction. 1998 — As part of a team including the Pasteur Institute, Karolinska Institute and Glaxo Wellcome Geneva, a NIDA-supported researcher identifies a brain receptor activated by nicotine use.

In an emergency?Need treatment?

• 2008 — NIDA’s Monitoring the Future Survey reveals an increased misuse of prescription medications and over-the-counter cough syrups among high school seniors, accounting for 8 of the top 13 drug categories reported by this group.
• Other molecules called transporters recycle neurotransmitters (that is, bring them back into the neuron that released them), thereby limiting or shutting off the signal between neurons.
• The 5S- or levo- stereoisomers of lysergamides do not exist in nature and are not formed during the synthesis from d-lysergic acid.
• Methamphetamine is a Schedule II stimulant, which means it has a high potential for abuse and is available only through a prescription that cannot be refilled.

In 2020, more than 93,000 Americans died from drug overdoses, marking the largest one-year increase in overdose deaths ever recorded, according to provisional data from the U.S. This increase has largely been driven by rising overdoses involving synthetic opioids, primarily fentanyl. Overdose deaths involving psychostimulants, and particularly methamphetamine, have also risen steeply in recent years, and many of these deaths involved use of an opioid at the same time. However, questions remain on how trends in methamphetamine use  contribute to greater risk for overdose deaths. Overdose deaths involving methamphetamine nearly tripled from 2015 to 2019 among people ages in the United States, according to a study by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health.

Do methamphetamine users go through withdrawal when they quit using the drug?

A properly functioning reward system motivates a person to repeat behaviors needed to thrive, such as eating and spending time with loved ones. Surges of dopamine in the reward circuit cause the reinforcement of pleasurable but unhealthy behaviors like taking drugs, leading people to repeat the behavior again and again. As with other diseases and disorders, the likelihood of developing an addiction differs from person to person, and no single factor determines whether a person will become addicted to drugs. In general, the more risk factors a person has, the greater the chance that taking drugs will lead to drug use and addiction. Dr. Volkow’s work has been instrumental in demonstrating that drug addiction is a brain disorder. As a research psychiatrist, Dr. Volkow pioneered the use of brain imaging to investigate how substance use affects brain functions.

In my last blog, I discussed that methamphetamine (or cocaine), in concert with fentanyl, is often a factor in overdose deaths in the United States. In this interview, I spoke with Jean Lud Cadet, MD, chief of the Molecular Neuropsychiatry Branch at the National Institute on Drug Abuse (NIDA) in Baltimore, Maryland. He also completed a psychiatry residency at Columbia University College of Physicians and Surgeons, where he was a medical student.

Physical Symptoms

One of the most significant ways that the Narconon program can help a methamphetamine addict is by offering the Narconon New Life Detoxification, one phase of the overall treatment program. This phase combines time in a low-heat sauna accompanied by moderate daily exercise and a strict nutritional regimen. According to a 2018 peer-reviewed study, this combination helps alleviate post-acute withdrawal symptoms as well as clarifying thinking and what is methamphetamine national institute on drug abuse nida reducing cravings. When the war ended for Japan, they had huge stockpiles of meth left over that they no longer needed for their pilots. They then began to distribute the unused drug to the Japanese public, creating an epidemic of methamphetamine addiction. The drug soon began to be restricted in country after country, with medical forms of the drug continuing to be sold under strict regulation.